Which stocks in any sector do Indian mutual fund managers prefer most? — August 2026 data
| # | Stock Name | No. of MFs Holding | Avg Weight (%) | Total MF Value (Cr) |
|---|---|---|---|---|
| 21 | GlaxoSmithKline Pharmaceuticals Limited | 125 funds | 0.82% | ₹2,607 Cr |
| 22 | Neuland Laboratories Limited | 123 funds | 1.80% | ₹3,875 Cr |
| 23 | Cohance Lifesciences Limited | 111 funds | 0.94% | ₹3,427 Cr |
| 24 | Piramal Pharma Limited | 103 funds | 1.27% | ₹3,772 Cr |
| 25 | Eris Lifesciences Limited | 93 funds | 1.03% | ₹3,309 Cr |
| 26 | Granules India Limited | 92 funds | 1.29% | ₹835 Cr |
| 27 | Onesource Specialty Pharma Limited | 92 funds | 1.43% | ₹2,360 Cr |
| 28 | Wockhardt Limited | 88 funds | 1.73% | ₹2,080 Cr |
| 29 | Natco Pharma Limited | 84 funds | 0.94% | ₹287 Cr |
| 30 | Pfizer Limited | 82 funds | 1.05% | ₹2,496 Cr |
| 31 | Emcure Pharmaceuticals Limited | 74 funds | 0.98% | ₹2,513 Cr |
| 32 | Jubilant Pharmova Limited | 68 funds | 0.99% | ₹1,050 Cr |
| 33 | Caplin Point Laboratories Limited | 66 funds | 0.74% | ₹308 Cr |
| 34 | Concord Biotech Limited | 60 funds | 0.71% | ₹879 Cr |
| 35 | Blue Jet Healthcare Ltd | 56 funds | 0.51% | ₹601 Cr |
| 36 | Rubicon Research Limited | 48 funds | 1.39% | ₹4,110 Cr |
| 37 | SANOFI CONSUMER HEALTHCARE | 41 funds | 0.55% | ₹1,353 Cr |
| 38 | Corona Remedies Limited | 40 funds | 0.92% | ₹1,589 Cr |
| 39 | Symbiotec Pharmalab Limited | 40 funds | 0.31% | ₹231 Cr |
| 40 | Alembic Pharmaceuticals Limited | 33 funds | 0.79% | ₹1,630 Cr |
The table above ranks the top 20 stocks in the Pharmaceuticals & Biotechnology sector by the number of Indian mutual fund schemes holding them as of August 2026. When a large number of fund managers independently choose the same stock, it is a powerful signal of institutional conviction — these are the stocks that professional money managers believe in most.
A stock held by 200+ mutual funds means that hundreds of fund managers — each doing their own independent research — have concluded that this stock deserves a place in their portfolio. This collective wisdom is one of the most reliable indicators of a stock's quality within its sector. The average weight shows how much of their portfolio each fund typically allocates to the stock, and the total MF value shows the combined rupee investment across all funds holding it.
All data is sourced from monthly portfolio disclosures that every AMFI-registered mutual fund is required to publish. RightAdvise compiles and analyses this data across 1,100+ active fund schemes to give you a clear, unbiased view of where professional fund managers are investing in the Pharmaceuticals & Biotechnology sector. Click any stock name in the table to see which specific funds hold it and in what proportion.